| Literature DB >> 34470627 |
Fereshteh Esfandiari1, Fereshteh Chitsazian2, Masoumeh Golestan Jahromi3, Raha Favaedi2, Masood Bazrgar2, Reza Aflatoonian4, Parvaneh Afsharian2, Abbas Aflatoonian5, Maryam Shahhoseini6,7,8.
Abstract
Endometriosis is major gynecological disease that affects over 10% of women worldwide and 30%-50% of these women have pelvic pain, abnormal uterine bleeding and infertility. The cause of endometriosis is unknown and there is no definite cure mainly because of our limited knowledge about its pathophysiology at the cellular and molecular levels. Therefore, demystifying the molecular mechanisms that underlie endometriosis is essential to develop advanced therapies for this disease. In this regard, HOX genes are remarkable because of their critical role in endometrial development and receptivity during implantation, which is attributed to their ability to mediate some of the sex steroid functions during the reproductive period. Access to the expression profiles of these genes would provide the necessary information to uncover new genes for endometriosis and assist with disease diagnosis and treatment. In this study we demonstrate an altered expression pattern for the HOX clusters (A-D) and their cofactors in both eutopic and ectopic conditions compared to control tissue biopsies. Remarkably, most of the intensive changes occurred in eutopic samples from endometriosis patients compared to control tissue biopsies. Pathway analysis revealed the involvement of differentially expressed genes in cancer that correlate with an association between endometriosis and cancer. Our results suggest critical roles for the HOX cluster and their cofactors in endometriosis pathophysiology.Entities:
Keywords: Endometriosis; Gene expression; HOX
Mesh:
Substances:
Year: 2021 PMID: 34470627 PMCID: PMC8409001 DOI: 10.1186/s12958-021-00816-y
Source DB: PubMed Journal: Reprod Biol Endocrinol ISSN: 1477-7827 Impact factor: 5.211
Fig. 1Gene expression array analysis for HOX genes. There were three biological repeats in each group. A, B, C and D in each graph show the nine data that were analyzed with SPSS software. P < 0.05 was considered to be significant
Fig. 2A Venn diagram for DEGs (P < 0.05). DEGs in the ectopic samples compared to normal samples (black ellipse), eutopic samples in comparison to normal samples (green ellipse), and ectopic samples compared to eutopic samples (red ellipse). Genes that were significantly upregulated are enclosed in black, green and red rectangles according to the above mentioned legend. In the multi-colored rectangles, each color represents upregulation in the relevant analysis in the corresponding agreement. B Heat map for all genes. Right column is logFC of ectopic samples compared to normal samples and the left column is the logFC of eutopic samples in comparison to normal samples. logFC: Logarithm fold change; UP: Significant upregulation; Down: Significant downregulation; None: Non-significant changes. C,D PCA analysis of gene expression in the nine sample groups. Triangle, circle, and square represent normal endometrial tissues of the control women, and ectopic endometrial tissues and eutopic endometrial tissues from patients, respectively. C: PCA of DEGs. D: PCA of non-DEGs
Fig. 3A Co-expression gene network. Blue, yellow, and green colors represent genes whose expressions significantly changed in the ectopic, eutopic and both tissues, respectively. B The number of genes with significant different expressions between sample tissues. All genes: The total number of nodes, Eutopic: Number of nodes with significant changes in gene expressions of the eutopic to control tissues, Ectopic: Number of nodes with significant changes in gene expression of the ectopic to control tissues, All DEGs: Number of nodes with significant changes in gene expressions of the patient to control tissues
Pathways with genes in the constructed networks in the study
| Gene symbol | ||||
|---|---|---|---|---|
| Network name | A | B | C | B |
| Pathway name | S | R | R | T |
R: Activation of anterior HOX genes in hindbrain development during early embryogenesis
S: Signaling pathways regulating pluripotency of stem cells
T: Transcriptional misregulation in cancer
List of diseases that show interference by the DEGs and genes from the five networks
| Description | Count | Percent | |
|---|---|---|---|
| Developmental | 19 | 44.19 | 2.14E-11 |
| Metabolic | 17 | 39.53 | 0.038479 |
| Neurological | 12 | 27.91 | 0.024028 |
| Cleft lip/Cleft palate | 8 | 18.60 | 1.21E-05 |
| Bone mineral density | 7 | 16.28 | 1.64E-04 |
| Vision | 7 | 16.28 | 0.002492 |
| Parkinson's disease | 4 | 9.30 | 0.003099 |
| Colobomatous microphthalmia | 3 | 6.98 | 1.86E-04 |
| Clubfoot | 3 | 6.98 | 0.001869 |
| Obstructive sleep apnea | 3 | 6.98 | 0.00642 |
| Hirschsprung's disease | 2 | 4.65 | 0.034825 |
| Developmental | 16 | 43.24 | 8.90E-09 |
| Neurological | 10 | 27.03 | 0.084075 |
| Psychological | 9 | 24.32 | 0.027439 |
| Cleft lip/Cleft palate | 6 | 16.22 | 8.20E-04 |
| Parkinson's disease | 5 | 13.51 | 1.46E-04 |
| Autism | 5 | 13.51 | 0.004516 |
| Bone mineral density | 5 | 13.51 | 0.007412 |
| Vision | 5 | 13.51 | 0.041046 |
| Metabolic | 13 | 46.43 | 0.03939 |
| Developmental | 12 | 42.86 | 1.51E-06 |
| Psychological | 11 | 39.29 | 1.60E-04 |
| Autism | 6 | 21.43 | 1.30E-04 |
| Cleft lip/Cleft palate | 6 | 21.43 | 2.09E-04 |
| Bone mineral density | 6 | 21.43 | 2.51E-04 |
| Parkinson's disease | 5 | 17.86 | 4.70E-05 |
| Talipes equinovarus | 2 | 7.14 | 0.005847 |
| Neurodevelopmental psychiatric disorders | 2 | 7.14 | 0.007304 |
| SIDS/sudden infant death syndrome | 2 | 7.14 | 0.038844 |
| Cleft lip/Cleft palate | 3 | 25 | 0.012792 |
| Cleft lip with and without cleft palate | 2 | 16.67 | 0.013342 |
| Bone mineral density | 3 | 25 | 0.013805 |
| Developmental | 4 | 33.33 | 0.023658 |
| Sleep apnea, obstructive | 2 | 16.67 | 0.026536 |
| Developmental | 7 | 46.67 | 1.47E-04 |
| Clubfoot | 3 | 20 | 1.97E-04 |
| Bone mineral density | 4 | 26.67 | 0.002301 |
| Metabolic | 9 | 60 | 0.004216 |
Other tissues in which the DEGs and the genes in five networks are expressed
| Description | Count | Percent | P-value | ||
|---|---|---|---|---|---|
| Cerebellum | 30 | 69.77 | 0.007552 | ||
| Salivary gland | 30 | 69.77 | 0.023191 | ||
| Lymphoma Burkitts Raji | 28 | 65.12 | 0.043332 | ||
| Adrenal cortex | 13 | 30.23 | 0.004518 | ||
| Craniofacial | 4 | 9.3 | 1.32E-06 | ||
| Retina | 4 | 9.3 | 0.036957 | ||
| Salivary gland | 26 | 70.27 | 0.005005 | ||
| Lymphoma Burkitts Raji | 25 | 67.57 | 0.005565 | ||
| Cerebellum | 25 | 67.57 | 0.008935 | ||
| BM-CD33 + myeloid | 24 | 64.86 | 0.010012 | ||
| Pons | 17 | 45.95 | 0.028449 | ||
| Adrenal cortex | 10 | 27.03 | 0.023199 | ||
| Craniofacial | 4 | 10.81 | 7.19E-07 | ||
| Ovary neoplasia | 3 | 8.11 | 0.033658 | ||
| Cerebellum | 19 | 67.86 | 0.002102 | ||
| Salivary gland | 19 | 67.86 | 0.005265 | ||
| Lymphoma Burkitts Raji | 18 | 64.29 | 0.012292 | ||
| Prostate | 17 | 60.71 | 0.015867 | ||
| BM-CD33 + myeloid | 17 | 60.71 | 0.03038 | ||
| Pons | 14 | 50 | 0.007547 | ||
| Eye_normal | 13 | 46.43 | 0.032975 | ||
| Craniofacial | 2 | 7.14 | 0.012725 | ||
| Uterine tumor_disease | 7 | 58.33 | 0.003695 | ||
| Embryo_development | 8 | 66.67 | 0.01666 | ||
| Cingulate cortex | 5 | 41.67 | 0.025441 | ||
| Heart | 6 | 50 | 0.047369 | ||
| Subthalamicnucleus | 6 | 40 | 0.020087 | ||
| Skin_normal | 7 | 46.67 | 0.027182 | ||
| Embryo_development | 10 | 66.67 | 0.032412 | ||
| Germ cell tumor_disease | 8 | 53.33 | 0.038866 | ||